C. K. Surratt

发表

Monoamine Transporter Structure, Function, Dynamics, and Drug Discovery: A Computational Perspective

J. Madura, Sankar Manepalli, C. K. Surratt, 2012, The AAPS Journal.

Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects

J. Madura, C. K. Surratt, W. Hong, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram.

Laura M. Geffert, M. Cascio, C. K. Surratt, 2018, Bioorganic & medicinal chemistry letters.

Editorial: In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other CNS-Active Drugs

J. Madura, C. K. Surratt, 2016, Front. Pharmacol..

New design strategies for antidepressant drugs

Laura M. Geffert, J. Madura, Kalyan Immadisetty, 2013, Expert opinion on drug discovery.

Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer

Jeffry D Madura, Christopher K Surratt, J. Madura, 2010, Proteins.

Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter

C. K. Surratt, O. Ukairo, Suneetha Ramanujapuram, 2007, Brain Research.

Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization.

Laura M. Geffert, J. Madura, Sankar Manepalli, 2011, ACS chemical neuroscience.

Evolution of a Required Service-Learning Course: Lessons Learned and Plans for the Future

Janet K. Astle, S. Desselle, C. K. Surratt, 2005 .

DARK Classics in Chemical Neuroscience: Ibogaine.

P. Witt-Enderby, C. K. Surratt, Michael J. Wasko, 2018, ACS chemical neuroscience.

Development of a neuroscience-oriented "methods" course for graduate students of pharmacology and toxicology.

C. Anderson, David A. Johnson, P. Witt-Enderby, 2006, CBE life sciences education.

Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

J. Foster, R. Vaughan, C. K. Surratt, 2011, Bioorganic & medicinal chemistry.

A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

J. Foster, R. Vaughan, C. K. Surratt, 2009, Bioorganic & medicinal chemistry.

Dopamine Transporter-Dependent and -Independent Striatal Binding of the Benztropine Analog JHW 007, a Cocaine Antagonist with Low Abuse Liability

A. Newman, C. K. Surratt, D. Donovan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High Throughput Docking and Pharmacophore Modeling.

J. Madura, C. K. Surratt, M. Indarte, 2010, ACS chemical neuroscience.

Mutation of human μ opioid receptor extracellular “disulfide cysteine” residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane

C. K. Surratt, Z. Wang, C. Zöllner, 1999 .

Control of mu opioid receptor expression by modification of cDNA 5'- and 3'-noncoding regions.

C. K. Surratt, P. Johnson, C. Zöllner, 2000, Brain research. Molecular brain research.

Calmodulin Regulation of Basal and Agonist‐Stimulated G Protein Coupling by the μ‐Opioid Receptor (OP3) in Morphine‐Pretreated Cell

W. Sadee, Danxin Wang, C. K. Surratt, 2000, Journal of neurochemistry.

Teaching Pharmacology Graduate Students how to Write an NIH Grant Application

R. Leak, C. K. Surratt, Lauren A. O'Donnell, 2015, American Journal of Pharmaceutical Education.

The “Research Track” Concentration, a New PharmD Elective Option

James K. Drennen, Christopher K. Surratt, J. Douglas Bricker, 2005 .

SPECIAL ARTICLES Succession Planning in US Pharmacy Schools

R. Blouin, C. K. Surratt, J. A. Amburgh, 2010 .

Properties of µ3 Opiate Alkaloid Receptors in Macrophages, Astrocytes, and HL-60 Human Promyelocytic Leukemia Cells

C. K. Surratt, K. Dobrenis, M. Makman, 1998 .

Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.

C. K. Surratt, P. Johnson, Z. Wang, 1999, Brain research. Molecular brain research.

G protein-coupled receptor structural motifs: relevance to the opioid receptors.

Christopher K Surratt, C. K. Surratt, Wendy R Adams, 2005, Current topics in medicinal chemistry.

Pharmacy students' perceptions of a teaching evaluation process.

S. Desselle, C. K. Surratt, 2007, American journal of pharmaceutical education.

Monoamine Transporter Structure, Function, Dynamics, and Drug Discovery: A Computational Perspective

J. Madura, Sankar Manepalli, C. K. Surratt, 2012, The AAPS Journal.

Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based Pharmacophore

Christopher K. Surratt, Jeffry D. Madura, Sankar Manepalli, 2011, J. Chem. Inf. Model..

Creation of a graduate oral/written communication skills course.

Christopher K Surratt, C. K. Surratt, 2006, American journal of pharmaceutical education.

Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.

Christopher K Surratt, C. K. Surratt, M. Sonders, 2003, Molecular pharmacology.

Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.

J. Madura, C. K. Surratt, Bernandie Jean, 2017, Journal of molecular graphics & modelling.

Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters

Christopher K. Surratt, C. K. Surratt, Okechukwu T. Ukairo, 2005, The AAPS Journal.

Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

R. Vaughan, C. K. Surratt, Tammy L. Nolan, 2012, ACS Medicinal Chemistry Letters.

Recognition of Benztropine by the Dopamine Transporter (DAT) Differs from That of the Classical Dopamine Uptake Inhibitors Cocaine, Methylphenidate, and Mazindol as a Function of a DAT Transmembrane 1 Aspartic Acid Residue

A. Newman, A. Kozikowski, C. K. Surratt, 2005, Journal of Pharmacology and Experimental Therapeutics.

(±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).

David J. Lapinsky, M. P. Blanton, R. Vaughan, 2012, Bioorganic & medicinal chemistry letters.

Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening

Laura M. Geffert, J. Madura, R. Leak, 2016, Pharmacology Biochemistry and Behavior.

Discovery of Novel-Scaffold Monoamine Transporter Ligands via in Silico Screening with the S1 Pocket of the Serotonin Transporter

Christopher K. Surratt, Jeffry D. Madura, Laura M. Geffert, 2014, ACS chemical neuroscience.

The Neuroscience Behind Drugs of Abuse: A PharmD Service-Learning Project

S. Desselle, C. K. Surratt, 2004 .

SERVICE LEARNING The Neuroscience Behind Drugs of Abuse: A PharmD Service-Learning Project

S. Desselle, C. K. Surratt, 2004 .

Research funding expectations as a function of faculty teaching/administrative workload.

C. K. Surratt, K. Kamal, P. Wildfong, 2011, Research in social & administrative pharmacy : RSAP.

Properties of mu 3 opiate alkaloid receptors in macrophages, astrocytes, and HL-60 human promyelocytic leukemia cells.

C. K. Surratt, K. Dobrenis, M. Makman, 1998, Advances in Experimental Medicine and Biology.

Spontaneous cleavage of RNA in ternary complexes of Escherichia coli RNA polymerase and its significance for the mechanism of transcription.

M. Chamberlin, C. K. Surratt, C. Surratt, 1991, Proceedings of the National Academy of Sciences of the United States of America.

A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets

Christopher K. Surratt, Jeffry D. Madura, J. Madura, 2015, Front. Neurol..

A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs

G. Uhl, E. Jabs, C. Griffin, 1993, FEBS letters.

Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based Pharmacophore

Laura M. Geffert, J. Madura, Sankar Manepalli, 2011, J. Chem. Inf. Model..

Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram.

Laura M. Geffert, M. Cascio, C. K. Surratt, 2018, Bioorganic & medicinal chemistry letters.

Preparation of misacylated aminoacyl-tRNA(Phe)'s useful as probes of the ribosomal acceptor site.

S. Hecht, C. K. Surratt, J. R. Roesser, 1989, Biochemistry.

INSTRUCTIONAL DESIGN AND ASSESSMENT The ''Research Track'' Concentration, a New PharmD Elective Option

J. Drennen, C. K. Surratt, J. Bricker, 2005 .

Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template

Jeffry D Madura, Christopher K Surratt, J. Madura, 2008, Proteins.

2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations

J. Madura, C. K. Surratt, W. Hong, 2016, The Journal of Pharmacology and Experimental Therapeutics.

β‐Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q μ‐opioid receptors

C. K. Surratt, C. Spivak, C. Zöllner, 2003, Synapse.